MTS Company CO., LTD.

At MTS, we are redefining the future of cancer diagnostics and research through advanced AI-powered digital pathology solutions. Our mission is to accelerate accurate, data-driven decision-making for pathologists, researchers, and healthcare institutions worldwide. Our Core Offerings: AI Diagnostic Models: High-performance AI algorithms designed to detect and classify major cancers with unmatched speed and accuracy. Mitotic Analysis & Biomarker Detection: Automated tools that enable precise mitotic count analysis and biomarker quantification to support predictive and personalized treatment strategies. Prediction: AI-driven models that forecast genetic mutations and treatment response, enabling more informed and proactive clinical decision-making. Research Partnerships: Collaborations with hospitals and research institutions to validate AI models across diverse datasets, driving innovation and reliability in clinical use. Why MTS: Accuracy & Speed: Our AI models are built to reduce diagnostic time while maintaining top-tier precision. Scalability: Flexible solutions tailored to both high-throughput laboratories and smaller clinical facilities. Innovation for Tomorrow: We’re committed to advancing digital pathology, predictive analytics, and AI-driven insights for oncology and beyond. At MTS, we believe that technology and pathology together can save lives by enabling earlier, faster, and more reliable cancer detection.